NanoViricides, Inc. (NYSE American: NNVC) has announced continued advancement of its broad-spectrum antiviral candidate NV-387 toward Phase II clinical development, with regulatory approval already obtained for a trial targeting MPox in the Democratic Republic of Congo. The company filed its quarterly report for the period ended March 31, 2026, detailing progress across multiple viral disease targets and an orphan-first regulatory strategy.
Following the quarter, the U.S. Food and Drug Administration granted orphan drug designation for NV-387 as a treatment for measles, and additional applications are pending for MPox and smallpox. The company's lead drug candidate, NV-387, is designed as a broad-spectrum antiviral with potential applications against respiratory syncytial virus (RSV), COVID-19, long COVID, influenza, MPox, smallpox, and measles. NanoViricides believes its nanoviricide technology, based on TheraCour Pharma's proprietary nanomaterials, offers a novel approach to antiviral therapy.
The company is focusing on advancing NV-387 into Phase II human clinical trials, with the MPox trial in the DRC representing a key milestone. Additionally, NanoViricides is developing two COVID-19 drug candidates: NV-CoV-2 (API NV-387) and NV-CoV-2-R, which encapsulates remdesivir. The company suggests that since remdesivir is already FDA-approved, NV-CoV-2-R could follow an expedited regulatory path if safety is comparable.
NanoViricides' pipeline also includes drugs for herpes simplex virus (HSV-1 and HSV-2), varicella-zoster virus (VZV), influenza, HIV, hepatitis C, rabies, dengue, and Ebola, among others. The company holds exclusive licenses to TheraCour's nanomedicine technology for several viral diseases, with plans to expand into RSV, poxviruses, and enteroviruses pending successful research.
As with any drug development, the company acknowledges the lengthy and capital-intensive process, and there is no assurance that any candidate will prove effective or safe in clinical trials. For more information on NanoViricides and its latest updates, visit https://ibn.fm/NNVC. The full press release is available at https://ibn.fm/osO0q.